Medy Tox (KOSDAQ:086900) posted first-quarter net income attributable to shareholders of 7.8 billion won, up 105% from 3.8 billion won a year earlier.
The South Korean biopharmaceutical company's sales declined 5.1% to 60.7 billion won from 64 billion won, according to a Tuesday filing with the Korea Exchange.
Shares of the company jumped nearly 7% in recent trade.